Fracture patterns, bisphosphonate treatment, and growth in TMEM38B-related osteogenesis imperfecta: a cohort study

Abstract Background Osteogenesis imperfecta (OI) type XIV, caused by biallelic TMEM38B mutations, is a rare, autosomal recessive form of OI, and data guiding optimal bisphosphonate treatment duration remain limited. Methods We retrospectively studied 23 patients, all homozygous for the same founder TMEM38B deletion (NM_018112.2: c.455_542del, p.Gly152Alafs*5), identified among a Bedouin population in southern Israel and followed between 2001 and 2026. Results Bisphosphonate treatment was initiated at a median age of 1.21 years and discontinued at a median age of 4.3 years, considerably earlier than reported in prior OI cohorts, most often for family-related reasons (12 of 20 patients who discontinued). Fracture frequency declined markedly with age, becoming infrequent beyond approximately age 11 years, around the time of puberty. Fracture-free survival after bisphosphonate discontinuation was low, with only 27% of patients who stopped before puberty remaining fracture-free at 2 years post-cessation, indicating that treatment was often stopped before fracture risk had fully resolved. Bone mineral density in later childhood was largely preserved, though DXA data were limited to a small subset. Vitamin D deficiency (< 50 nmol/L) was found in 57% of patients, while other metabolic bone parameters were normal. Height clustered near the 3rd percentile for age, and four patients (17%) remained wheelchair-dependent. Conclusions To our knowledge, this is the largest reported cohort of TMEM38B-related OI to date. Our findings suggest that fracture risk in this genetically homogeneous population declines around puberty, whereas treatment was usually discontinued years earlier, most often because families did not return for further treatment courses, highlighting a need for evidence-based guidelines on bisphosphonate treatment duration in this rare type of OI.

Authors

Institutions

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-16
DOI
https://doi.org/10.1186/s13023-026-04716-5
Primary Topic
Connective tissue disorders research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fracture patterns, bisphosphonate treatment, and growth in TMEM38B-related osteogenesis imperfecta: a cohort study

David Shaki, Inbar Gehasi, Lior Carmon, Eli Hershkovitz et al.
Orphanet Journal of Rare Diseases
Connective tissue disorders research
article

Fracture patterns, bisphosphonate treatment, and growth in TMEM38B-related osteogenesis imperfecta: a cohort study

David Shaki, Inbar Gehasi, Lior Carmon, Eli Hershkovitz, Majd Nassar, Eyal Kristal, Alon Haim, Galina Ling, Odeya David, Neta Loewenthal
article en

Abstract

Abstract Background Osteogenesis imperfecta (OI) type XIV, caused by biallelic TMEM38B mutations, is a rare, autosomal recessive form of OI, and data guiding optimal bisphosphonate treatment duration remain limited. Methods We retrospectively studied 23 patients, all homozygous for the same founder TMEM38B deletion (NM_018112.2: c.455_542del, p.Gly152Alafs*5), identified among a Bedouin population in southern Israel and followed between 2001 and 2026. Results Bisphosphonate treatment was initiated at a median age of 1.21 years and discontinued at a median age of 4.3 years, considerably earlier than reported in prior OI cohorts, most often for family-related reasons (12 of 20 patients who discontinued). Fracture frequency declined markedly with age, becoming infrequent beyond approximately age 11 years, around the time of puberty. Fracture-free survival after bisphosphonate discontinuation was low, with only 27% of patients who stopped before puberty remaining fracture-free at 2 years post-cessation, indicating that treatment was often stopped before fracture risk had fully resolved. Bone mineral density in later childhood was largely preserved, though DXA data were limited to a small subset. Vitamin D deficiency (< 50 nmol/L) was found in 57% of patients, while other metabolic bone parameters were normal. Height clustered near the 3rd percentile for age, and four patients (17%) remained wheelchair-dependent. Conclusions To our knowledge, this is the largest reported cohort of TMEM38B-related OI to date. Our findings suggest that fracture risk in this genetically homogeneous population declines around puberty, whereas treatment was usually discontinued years earlier, most often because families did not return for further treatment courses, highlighting a need for evidence-based guidelines on bisphosphonate treatment duration in this rare type of OI.

Orphanet Journal of Rare Diseases
Ben-Gurion University of the Negev (IL), Soroka Medical Center (IL)
Good health and well-being
Connective tissue disorders research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon